Michael Gold, M.D.

Dr. Michael Gold has served as our Chief Medical Officer since January 2023. From May 2017 to January 2023, Dr. Gold served as Vice President, Therapeutic Head CNS Development at AbbVie, where he was responsible for AbbVie’s CNS pipeline and was involved in the successful approval of CNS therapies including VRAYLAR as an adjunctive treatment for major depressive disorder. Prior to that, Dr. Gold held leadership roles at a number of biopharmaceutical companies, including as vice president at PPD from July 2015 to May 2017 and as vice president at UCB from January 2013 to June 2015. He also held a faculty position in the Department of Neurology at the University of South Florida, where he also served as the Medical Director for the Memory Disorder Clinic. 

Dr. Gold holds a B.S. in Chemistry, an M.S. in Mathematics and Computer Science and an M.D.from the University of Miami. He completed a Neurology residency at the Albert Einstein College of Medicine and a fellowship in Behavioral Neurology at the University of Florida College of Medicine.